SCHEMBL6791903

SCHEMBL6791903

COC(=O)c1cc(C)ccc1NC(=O)/C=C(/C)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.43
ALDH1A1 P00352 5/20 0.42
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 4/20 0.41
HPGD P15428 3/20 0.41
TAS1R3 Q7RTX0 2/20 0.40
TAS1R1 Q7RTX1 2/20 0.40
TAS1R2 Q8TE23 2/20 0.40
LMNA P02545 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
LTB4R Q15722 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785976 0.90 TERT (0.44) TERTALDH1A1MAPTMEN1KMT2A
SCHEMBL6783775 0.88 TERT (0.54) TERTALDH1A1MAPTMEN1KMT2A
SCHEMBL6787326 0.88 TERT (0.42) TERTALDH1A1MAPTMEN1KMT2A
SCHEMBL6784249 0.86 TERT (0.56) TERTALDH1A1MAPTMEN1KMT2A
SCHEMBL6787614 0.84 KDM4E (0.53) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL6785982 0.84 ALDH1A1 (0.46) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL6786604 0.83 TERT (0.53) TERTALDH1A1MAPTMEN1KMT2A
SCHEMBL6784075 0.83 ALDH1A1 (0.51) TERTALDH1A1MAPTMEN1KMT2A
SCHEMBL6786599 0.79 LMNA (0.47) TERTALDH1A1MAPTMEN1KMT2A
SCHEMBL6785267 0.78 KDM4E (0.57) TERTKDM4EPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885ALDH1A1 102/4885MAPT 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.